REVIEW ARTICLE
The impact of systemic administration of polyphenols on periodontitis associated with diabetes mellitus: a systematic review
Kornelija Rogalnikovaitea, Auste Antipovieneb, Asta Burbulytec and Egle Aida Bendoraitienea
aDepartment of Preventive and Paediatric Dentistry, Lithuanian University of Health Sciences, Kaunas, Lithuania; bDepartment of Dental and Oral Pathology, Lithuanian University of Health Sciences, Kaunas, Lithuania; cLibrary and Information Centre, Information Services Division, Lithuanian University of Health Sciences, Kaunas, Lithuania
ABSTRACT
Objective: The aim of this work was to explore the potential of polyphenol supplement consumption in enhancing the treatment of periodontitis and diabetes mellitus in both diabetic animals and humans.
Materials and methods: A comprehensive search across eight databases (MEDLINE, EBSCO, Taylor & Francis, PRIMO, Web of Science, Wiley Online Library, ScienceDirect, and SAGE Journals) and two registers (ClinicalTrials.gov and Cochrane Library Trials) was conducted. Methodological quality assessment employed the Cochrane Collaboration Risk of Bias Assessment Tool for randomised controlled trials and the Systematic Review Centre for Laboratory Animal Experimentation Risk of Bias Tool for experimental animal studies.
Results: Ten articles meeting inclusion criteria were identified. Three clinical studies demonstrated significant reductions in probing depth (PD) and clinical attachment loss (CAL). Ginger supplementation showed a decrease in CAL (–0.57 ± 0.50 vs. –0.14 ± 0.35, p = 0.003) and PD (–0.52 ± 0.51 vs. –0.19 ± 0.51, p = 0.04), while resveratrol supplementation exhibited a reduction in PD (–1.1 ± 0.58 vs. –0.6 ± 0.47, p < 0.001). Additionally, cranberry juice supplementation led to a decrease in PD (–0.56 ± 0.03, p < 0.001). However, there was no significant improvement in inflammation status. Although polyphenol supplementation did not impact fasting blood glucose levels, it did result in improved insulin resistance (3.66 ± 0.97 vs. 4.49 ± 1.56, p = 0.045). In diabetic animals, six studies reported a significant reduction (p < 0.05) in bone loss along with marked improvements in inflammation status.
Conclusions: Despite the promising results observed in the included studies, the overall evidence supporting the positive effects of polyphenols on periodontal and diabetes mellitus status, along with their anti-inflammatory properties, remains inadequate.
KEYWORDS: Diabetes mellitus; periodontitis; polyphenols; inflammation
Citation: ACTA ODONTOLOGICA SCANDINAVICA 2024; VOL. 83: 238–248. DOI: https://doi.org/10.2340/aos.v83.40484.
Copyright: © 2024 The Author(s). Published by MJS Publishing on behalf of Acta Odontologica Scandinavica Society. This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
Received: 8 November 2023; Accepted: 8 December 2024; Published: 3 May 2024.
CONTACT Kornelija Rogalnikovaite kornelijarogal@gmail.com Department of Preventive and Paediatric Dentistry, Lithuanian University of Health Sciences, Kaunas, Lithuania
Competing interests and funding: The authors report there are no competing interests to declare.
No funding was obtained for this study.
Introduction
Periodontitis is a chronic inflammatory disease that leads to the destruction of the periodontal ligament, connective tissue, and alveolar bone. It affects up to 62% of the adult population [1]. In addition to tissue destruction and tooth loss, periodontal disease and the presence of associated pathogens such as Porphyromonas gingivalis, Aggregatibacter actinomycetemcomitans, and Fusobacterium nucleatum have now been linked to a wide spectrum of extra-oral diseases. These include Alzheimer’s disease [2], diabetes mellitus (DM) [3], cardiovascular disease [4], colorectal cancers [5], inflammatory bowel disease [6], rheumatoid arthritis [7], non-alcoholic fatty liver disease [8], and obesity [9]. The periodontal microbiota exerts an impact on systemic diseases through two primary and potentially synergistic mechanisms: direct disease-promoting effects resulting from the migration of oral bacteria to distant locations and a variety of indirect effects due to the presence of imbalanced oral microbial communities in the mouth [10]. The relationship between periodontal disease and other inflammatory conditions is not fully understood, and ongoing debates exist, considering its bidirectional nature [11].
While changes in the oral microbiota play a specific role in the development of periodontitis, its aetiology is multifactorial [12]. The host response to microbial invasion involves the upregulation of proinflammatory cytokines, matrix metalloproteinases, and reactive oxygen species (ROS) [13, 14]. ROS help to eliminate periodontal pathogens, but if overstimulated, they can lead to connective tissue destruction and periodontal attachment loss due to oxidative stress – an imbalance between the production and elimination of reactive oxygen/nitrogen species (ROS/RNS) [14]. Oxidative stress is a common characteristic of chronic periodontitis and other systemic inflammatory diseases, such as obesity or DM [13, 15, 16].
Considering oxidative stress as a therapeutic target for chronic periodontitis, antioxidants are believed to be beneficial as adjuncts to periodontal treatment. Polyphenols, a class of compounds found in many plant foods, play a potential pro-oxidant role and protect our bodies from severe cellular oxidative stress [17]. Their antioxidant effect makes them beneficial in preventing and treating several inflammatory diseases, such as type 2 diabetes mellitus (T2DM) [18] and Alzheimer’s disease [19]. Given the well-analysed relationship between periodontal diseases and DM, particularly the high prevalence in diabetic patients [20, 21], the aim of this systematic review is to investigate whether polyphenol supplement consumption could improve the treatment of periodontitis and DM both diabetic animals and humans.
Materials and methods
Protocol and registration
The systemic analysis review report adhered to the Preferred Reporting Item for Systematic Review and Meta-Analyses (PRISMA) statement [22]. The review was registered on PROSPERO system under number CRD42023402629.
Focus question
The following focus question was formulated using the Population, Intervention, Comparison, and Outcome (PICO) framework (Table 1): Is there evidence to suggest that the administration of polyphenols as a systemic treatment can influence the regression of periodontitis and improve the diabetic condition in individuals and animal models with DM?.
Information sources and search strategy
An information professional (A.B.) conducted an electronic search in a total of eight databases and two registers from October 27, 2022 to December 1, 2022. The search was performed in the following sources: MEDLINE (PubMed), EBSCO, Taylor & Francis, PRIMO, Web of Science, Wiley Online Library, ScienceDirect, SAGE Journals, ClinicalTrials.gov, and Cochrane Library Trials. To minimise the inclusion of irrelevant articles, an additional filter of ‘dentistry’ was applied specifically to the Wiley Online Library database. The search utilised Medical Subject Headings (MeSH) terms, namely ‘polyphenols’, ‘periodontitis’, and ‘periodontal diseases’ combined using the Boolean operator ‘AND’. The search strategy is presented in Table 2.
Selection of studies
The titles and abstracts of all the studies identified, as well as the full text of potentially eligible investigations, were independently screened by two review authors (K.R. and A.A.) using predefined inclusion and exclusion criteria. In cases where there was a disagreement regarding the eligibility of articles, a third reviewer (E.A.B.) was involved to resolve any conflicts through collaboration.
Inclusion and exclusion criteria
The following inclusion criteria were applied during the screening process:
- Randomised controlled trials (RCTs) and experimental animal studies
- T2DM patients with periodontitis
- Mice and/or rats with type 1 diabetes mellitus (T1DM) or T2DM induced using streptozotocin solution, with experimental periodontitis induced by the ligation method
- Systemic administration of polyphenols for a minimum duration of 28 days
- Assessment of changes in clinical periodontal parameters, including periodontal bone level (PBL), alveolar bone loss (ABL), probing depth (PD), and/or clinical attachment loss (CAL)
- Analysis of changes in the expression and levels of inflammatory mediators, fasting blood glucose (FBG), glycosylated haemoglobin levels (HbA1c), and glycaemic index
- Studies published from January 1, 2012
- Studies written in the English language
- Full-text access to the articles
The following exclusion criteria were also applied:
- Clinical or preclinical trials without a control group
- Studies involving systemically healthy patients with periodontitis
- Experimental periodontitis studies in mice and/or rats without a DM model
- Local administration of polyphenols
- The duration of systemically administered polyphenols was less than 28 days
- Systematic reviews, letters, dissertations, case reports, conference abstracts, and theses
Data extraction
A narrative synthesis was conducted by two independent review authors, K.R. and A.A., using studies that met the inclusion criteria. The studies were categorised into two groups: investigations reporting the effect of systemic administration of polyphenols on periodontal tissues, inflammation markers and diabetes condition in patients with DM and separately in diabetic animals. The pertinent information was synthesised by tabulating the data according to (1) authors and year, (2) study design, (3) study population, (4) interventions, (5) experimental period, (6) analysed parameters, and (7) results.
Risk of bias assessment
During the data extraction process, the methodological quality of the included studies was assessed by two independent reviewers (K.R. and A.A.). Similarly, in situations where disagreements arose regarding the risk of bias, a third reviewer (E.A.B.) was engaged to facilitate consensus and resolve any conflicts through collaborative discussion.
For RCTs, the risk of bias was analysed using the Cochrane Collaboration Risk of Bias Assessment Tool [23]. The following parameters were evaluated to determine the risk of bias: (1) random sequence generation, (2) allocation concealment, (3) blinding of participants and personnel, (4) blinding of outcome assessment, (5) incomplete outcome data, (6) selective reporting, and (7) other biases. The risk of bias was classified as low (+), high (–), or unclear (×) for each parameter. Studies were categorised as having a low risk of bias if all criteria were met, unclear if one criterion was not met or the risk of bias was unclear for two criteria and high if two or more criteria were not met.
For the included animal studies, the risk of bias was assessed using the Systematic Review Centre for Laboratory Animal Experimentation Risk of Bias (SYRCLE’s RoB) Tool [24]. This tool includes 10 entries related to six types of bias: (1) selection bias, (2) performance bias, (3) detection bias, (4) attrition bias, (5) reporting bias, and (6) other biases. The risk of bias was classified as ‘high’ (–), ‘low’ (+), or ‘unclear’ (?) if there were insufficient details reported to properly assess the risk of bias.
Results
Study selection
The search strategy in electronic databases and registers initially identified 1,742 investigations. All records were exported to RefWorks® (ProQuest CSA, Bethesda, MD, United States) bibliography and citation manager. After removing duplicates, a total of 1,137 articles remained for screening. Based on the titles, 996 articles were excluded. Following this exclusion, a more detailed screening was conducted on the remaining 141 articles’ abstracts. From this screening, 12 publications were identified as meeting the criteria for full-text analysis. Two of them were further excluded for the following reasons: one study administered polyphenols as a local application in diabetic rats [25], and another study’s results were not yet available as it was a completed clinical trial registered on the Cochrane Central Register of Controlled Trials [26]. Finally, a total of 10 articles were included in the systematic review. The study selection process is presented in Figure 1.
Figure 1. PRISMA flow diagram.
Risk of bias assessment
After assessing the methodological quality of RCTs, it was identified that three clinical trials [27–29] were at a high risk of bias. The study conducted by Gholinezhad et al. [30] was rated as having high quality based on the evaluation criteria. A detailed assessment of the risk of bias is presented in Figure 2.
Figure 2. Assessment of risk of bias for clinical studies.
Regarding the preclinical studies with animals, the quality assessment revealed that all of them were classified as high risk in the domains of ‘allocation concealment’, ‘random outcome assessment’ and ‘performance blinding’. Additionally, there was insufficient information provided regarding animal housing during the experiments. For the entry ‘selective outcome reporting’, all expected outcomes were reported, indicating a low risk of bias. Most of the studies showed a low risk of bias for the items ‘detection blinding’, ‘incomplete outcome reporting’, and ‘other biases’, with 67% and 83% of studies demonstrating low risk, respectively. These findings are summarised in Table 3 and Figure 3.
| Author, year | Sequence generation | Baseline characteristics | Allocation concealment | Random housing | Performance blinding | Random outcome assessment | Detection blinding | Incomplete outcome data | Selective outcome reporting | Other sources of bias |
| Alpan et al., 2022 [31] | + | ? | – | ? | – | – | + | + | + | + |
| Catanzaro et al., 2018 [32] | – | + | – | ? | – | – | + | + | + | + |
| Cirano et al., 2021 [33] | – | + | – | ? | – | – | + | + | + | + |
| Gennaro et al., 2015 [34] | – | – | – | ? | – | – | ? | – | + | + |
| Toker et al., 2018 [35] | – | ? | – | ? | – | – | + | + | + | – |
| Zhen et al., 2015 [36] | + | + | – | ? | – | – | – | ? | + | + |
| +: low risk; ?: unclear risk; –: high risk. | ||||||||||
Figure 3. A summary of risk of bias for each item in the SYRCLE.
Characteristics of included studies
The characteristics of the included studies are described in Tables 4 and 5. This systematic review included a total of four RCTs [27–30] and six preclinical animal studies [31–36]. The study population consisted of 169 patients and 216 animals, specifically 196 Wistar rats and 20 C57BLKS/J-db/db mice. The experimental period in clinical trials ranged from 4 [27, 29] to 8 [28, 30] weeks, while in preclinical studies, it ranged from 28 [36] to 90 [32, 34] days. The administered polyphenols varied among the studies, with the most used ones being resveratrol [27, 29, 33, 36], ginger [30], cranberry juice [28], green tea extract [32, 34], taxifolin [31], and grape seed proanthocyanidin extract [35]. In the case of diabetic patients with periodontitis, polyphenol supplementation was administered orally as tablets, except for cranberry juice, which was consumed in liquid form. Rats and mice received different polyphenols via gavage [31, 33, 35, 36] or ad libitum [32, 34]. DM was induced in animals by intraperitoneal injection of streptozotocin, with concentrations ranging from 47 [32] to 60 mg/kg [33, 35]. One study by Zhen et al. [36] utilised C57BLKS/J-db/db mice, which are a model of T2DM. Experimental periodontitis was induced by ligation with 4-0 silk sutures [31, 35] or cotton ligatures [33, 36]. In the study by Zhen et al. [36], cotton ligatures were pre-soaked in a medium with P. gingivalis. However, in the studies by Catanzaro et al. [32] and Gennaro et al. [34], no ligation was performed. Given the fact that DM can worsen periodontal diseases, the authors of the included studies analysed the possible changes in periodontal tissues caused by hyperglycaemia. PD was evaluated in three clinical trials [27, 28, 30], while CAL was assessed in two of four selected studies [29, 30]. In addition, the majority of included articles focused on total antioxidant capacity [29, 30], HbA1c [28, 30] and FBG [27, 28, 30]. Furthermore, Javid et al. [27] measured insulin levels and utilised the homeostasis model to assess insulin resistance. In all preclinical studies [31–36], ABL or PBL was measured. Some investigations also evaluated changes in the expression of cytokines, inflammatory markers, or oxidative stress markers, with receptor activator of nuclear factor kappa-B ligand (RANKL) [31, 34], osteoprotegerin (OPG) [33, 34], interleukins (ILs) [33, 34, 36], and tumour necrosis factor alpha (TNF-α) [34, 36] being among the markers of interest. Concerning diabetes condition, blood glucose levels [31, 33, 35, 36] and the glycaemic index [32, 34] were assessed in diabetic animals.
| Author | Gholinezhad et al. [30] | Javid et al. [27] | Javid et al. [28] | Javid et al. [29] |
| Publication year | 2020 | 2017 | 2017 | 2019 |
| N total N intervention N placebo |
42 21 21 |
43 21 22 |
41 I1 = 10; I2 = 9; I3 = 10 12 |
43 21 22 |
| Study design | RCT | RCT | RCT | RCT |
| Intervention group | Ginger supplement 2 g/d as four tablets ( 2× daily 2 tablets) + NST | 480 mg/d resveratrol (2 pills) + NST | I1 omega-3, 1g/2 times a day I2 cranberry juice 200 ml 2 times a day I3 cranberry juice enriched with omega-3,200 ml + 1 g omega-3 2 times a day |
480 mg/d resveratrol (2 pills) + NST |
| Control group | Placebo + NST | Placebo capsules (2 pills) + NST | NST | Placebo capsules (2 pills) + NST |
| Type of intervention | Ginger supplement + NST | Resveratrol + NST | Omega-3 or cranberry juice or omega-3 with omega-3 + NST | Resveratrol + NST |
| Duration of intervention | 8 weeks | 4 weeks | 8 weeks | 4 weeks |
| Periodontal status results | ↓ΔCAL (−0.57 ± 0.50 vs. −0.14 ± 0.35, p = 0.003); ↓ΔPD (−0.52 ± 0.51 vs. −0.19 ± 0.51, p = 0.04) | ↓ΔPD (−1.1 ± 0.58 vs. −0.6 ± 0.47, p < 0.001) | ↓ΔPD (−0.77 ± 0.3 vs. −0.56 ± 0.03 vs −1.08 ± 0.49 vs. −0.9 ± 4.9, p < 0.001) | ΔCAL not evaluated;post-intervention CAL (2 ± 0.4 vs. 2.2 ± 0.5, p = 0.06) |
| Inflammation status results | ΔTAC (−0.006 ± 0.09 vs. 0.014 ± 0.03, p = 0.33); ΔMDA (−0.13 ± 8.66 vs. −3.37 ± 7.16, p = 0.19) | − | − | ΔIL-6, ΔTNF-α, ΔTAC not evaluated; post-intervention IL-6 (1.58 ± 1.06 vs. 1.85 ± 0.59, p = 0.3); TNF-α (10.33 ± 0.66 vs. 10.57 ± 0.68, p = 0.25); TAC (1.35 ± 0.62 vs. 1.02 ± 0.43, p = 0.05) |
| Diabetic status results | ↓ΔHbA1C (−0.75 ± 1.17 vs. −0.16 ± 0.44, p = 0.04); ΔFBG (−2.57 ± 27.05 vs. −19.04 ± 39.49, p = 0.12) | FBG (9.19 ± 2.78 vs. 7.9 ± 2.12, p = 0.097); ↓insulin (10.42 ± 0.28 vs. 10.92 ± 0.9, p = 0.02), ↓HOMA-IR (3.66 ± 0.97 vs 4.49 ± 1.56, p = 0.045) | ΔFBG (−31.40 ± 64.73 vs.−28.00 ± 46.89 vs. −3.11 ± 69.29 vs. 5.57 ± 38.87, p = 0.492);ΔHbA1C (−0.29 ± 0.67 vs. −0.87 ± 0.86 vs. −0.25 ± 0.51 vs. −0.40 ± 0.42, p = 0.2) | − |
| Conclusions | Positive effect on periodontal and diabetes status in patients with DM. | Positive effect on periodontal and diabetes status in patients with DM. | Positive effect on periodontal status in patients with DM. | No positive effect on periodontal status in patients with DM. |
| RCT: randomised controlled trial; I: intervention; NST: non-surgical periodontal treatment; ΔCAL: changes in clinical attachment loss; ΔPD: changes in pocket depth; ΔHbA1c: changes in glycosylated haemoglobin levels; DM: diabetes mellitus; HOMA-IR: insulin resistance; ΔFBG: changes in fasting blood glucose; ΔTAC: changes in total antioxidant capacity; ΔMDA: changes in malondialdehyde; TNF-α: tumour necrosis factor; IL-6: interleukin 6; ↑/↓: statistically significant decrease, resp. increase in comparison of test/control group. | ||||
| Author, year | Alpan et al., 2022 [31] | Catanzaro et al., 2018 [32] | Cirano et al., 2021 [33] | Gennaro et al., 2015 [34] | Toker et al., 2018 [35] | Zhen et al., 2015 [36] |
| Study design | Experimental animal study | Experimental animal study | Experimental animal study | Experimental animal study | Experimental animal study | Experimental animal study |
| N total N intervention N control |
30 I1 = 10; I2 = 10 C = 10 |
50 I = 25 C = 25 |
54 I1 = 13; I2 = 14 C1 = 14; C2 = 15 |
40 I = 20 C = 20 |
22 I1 = 8; I2 = 8 C = 6 |
20 I = 10 C = 10 |
| Intervention group | I1 Taxi-5 I2 Taxi-10 29 days |
GT ad libitum 90 days |
10 mg/kg of RSV I1 – DM+RSV I2 – DM+INS+RSV 30 days |
GT ad libitum 90 days |
I1 GSPE-100 I2 GSPE-200 30 days |
20 mg/kg of RSV 4 weeks |
| Control group | Untreated mice with DM and PE | Distilled water ad libitum | C1 – DM+PL C2 – DM+INS |
Distilled water ad libitum | Untreated mice with DM and PE | Untreated mice with DM and PE |
| Periodontal status results | ↓bone loss (p < 0.05);↑ BMP-2 (1.14 ± 0.01 vs. 2.00 ± 0.81 vs. 2.85 ± 0.37, p < 0.05); ↑ type I collagen (0.42 ± 0.20 vs. 1.85 ± 0.89 vs. 2.14 ± 0.89, p < 0.05); ↑ ALP (0.42 ± 0.20 vs. 1.85 ± 0.69 vs. 2.71 ± 0.48, p < 0.05); ↑ OCN (1.42 ± 0.20 vs. 2.00 ± 0.57 vs. 2.28 ± 0.95, p < 0.05); ↑ BCL-2 (0.14 ± 0.01 vs. 1.85 ± 0.89 vs. 2.28 ± 0.95, p < 0.05) | ↓bone loss PBL (1.34 ± 0.21 vs. 0.93 ± 0.11, p < 0.05) | I1 ↓bone loss (p < 0.05) | ↓bone loss (ABC-CEJ 468.4 ± 61.4 vs. 341.5 ± 26.1, p < 0.05) | ↓bone loss in I2 (p < 0.05), ↑osteoblast activity (p < 0.05) | ↓bone loss (p < 0.05) |
| Inflammation status results | ↓Bax (2.28 ± 0.48 vs. 1.42 ± 0.53 vs. 1.14 ± 0.69, p < 0.05); ↓RANKL in I2 (1.85 ± 0.69 vs 0.28 ± 0.18, p < 0.05) | – | I2 ↓ IL-1β (p < 0.05), ↓ IL-6 (p < 0.05), ↑SOD (p < 0.05), I1 ↓ NADPH oxidase (p < 0.05), I1 ↓OPG (6.143 ± 4.552 vs. 1.098 ± 1.646, p < 0.05), I1 ↑SIRT mRNA(28.127 ± 27.094 vs. 4.590 ± 5.712, p < 0.05), I1↓RANKL(42.653 ± 24.813 vs. 49.616 ± 28.662, p < 0.05) | ↓ IL-10 (1740.9 ± 38 vs. 955.1 ± 114.4, p < 0.05), ↑OPG(2211.5 ± 74.6 vs 1791.6 ± 78.3, p < 0.05), ↓ RANKL (1046.7 ± 31.6 vs 1653.6 ± 41.9, p < 0.05, ↓TNF-α (1,141 ± 71 vs. 1,653 ± 104, p < 0.05), ↑RUNX-2 (p < 0.05) | ↓ inflammatory cells (p < 0.05), ↓(MMP)-8 (200.07 ± 29.00 vs. 91.77 ± 48.00 vs 52.72 ± 24.39, p < 0.05), ↓(HIF)-1α (150.50 ± 44.03 vs. 81.98 ± 44.19 vs. 74.13 ± 28.23, p < 0.05) | ↓ IL-1β, IL-6, IL-8 (p < 0.05), ↓TNF-α (p < 0.05), ↓TLR4 (p < 0.05) |
| Diabetes status results | Blood glucose (444.71 ± 32.73 vs. 472.85 ± 14.97 vs. 433.71 ± 31.62, p > 0.05) | ↓Glycaemic level (284.4 vs. 357.2, p < 0.05) | I1 ↓ glucose level (282.07 ± 7 vs. 445.92 ± 7, p < 0.05) | ↓Mean glucose level (281.2 ± 21.4 vs. 361.7 ± 16.0, p < 0.05) | Blood glucose (444.0 ± 36.0 vs. 447.0 ± 36.0 vs 451.0 ± 35.0, p > 0.05) | ↓Fast plasma glucose (p < 0.05) |
| I: intervention; C: control; Taxi-5: taxifolin 5 mg/kg; Taxi-10: taxifolin 10 mg/kg; DM: diabetes mellitus; PE: experimental periodontitis; BMP-2: bone morphogenic protein; OCN: osteocalcin; ALP: alkaline phosphatase; BAX: pro-aptotic Bax protein; Bcl-2B: protein regulator of apoptosis; RANKL: receptor activator of nuclear factor kappa-B ligand; GT: green tea; PBL: periodontal bone level; RSV: resveratrol; PL: placebo; INS: insulin therapy; IL-1β: interleukin 1β; IL-6: interleukin 6; IL-7: interleukin 7; SOD: superoxide dismutase 1; NADPH oxidase: nicotinamide adenine dinucleotide phosphatase oxidase; OPG: osteoprotegerin; SIRT 1: Sirtuin 1; ABC: alveolar bone crest; CEJ: cementoenamel junction; RUNX-2: runt-related transcription factor 2; IL-10: interleukin 10; TNF-α: tumour necrosis factor alfa; GSPE-100: grape seed proanthocyanidin extract 100 mg/kg/day; GSPE-200: grape seed proanthocyanidin extract 200 mg/kg/day; (MMP)-8: matrix metalloproteinase; (HIF)-1α: hypoxia inducible factor; IL-8: interleukin 8; TLR4: Toll-like receptor 4; IFN-γ: interferon-gamma; ↑/↓: statistically significant decrease, resp. increase in comparison of test/control group. | ||||||
Discussion
The current systematic review is primarily focused on assessing the supplementary systemic administration of polyphenols in individuals and mice with DM. It is widely acknowledged that polyphenols can exert localised effects in the treatment of periodontitis by promoting beneficial oral bacterial communities and suppressing inflammation [37–42]. Furthermore, these compounds can also have downstream effects or function through phenolic metabolites to mitigate inflammatory and metabolic issues linked to diabetes [37]. Local applications of polyphenols have shown favourable outcomes in periodontal treatment, demonstrating antibacterial and immunomodulatory properties [38, 39]. Das et al. [40] illustrated that grape seed extract, when used in conjunction with scaling and root planing, significantly reduced measures of periodontal disease, including PD and relative attachment level (RAL). Similarly, Chava et al. [41] reported that a thermo-reversible green tea catechin gel reduced PD and RAL, Elavarasu et al. [42] demonstrated that curcumin strips acted as antioxidants, lowering superoxide dismutase levels. However, it is important to notice that localised applications of polyphenols do not alter the host immune response to chronic bacterial infection as does systemic consumption [43].
Polyphenols have been studied for their beneficial effects on various diseases due to their anti-inflammatory and antioxidant properties. Chedea et al. [44] raised the question of whether grape pomace polyphenols could be used as an alternative or adjuvant treatment to non-steroidal anti-inflammatory drugs to minimise side effects. Grape pomace was found to have promising potential in reducing oxidative stress and inflammation markers, as evidenced in various in vivo and in vitro studies. The synthesis of various polyphenols is believed to have a synergistic effect and may be more effective than single compound polyphenols, warranting further investigation. It is worth noting that other natural micronutrients, such as carotenoids and vitamins, also possess antioxidant properties and function as anti-inflammatory agents. Their actions may complement and synergise with those of polyphenols, both in dietary contexts and as potential supplementary therapeutic agents [37]. Considering those drawbacks of systemic polyphenols administration, it may have limited effectiveness due to the unfavourable pharmacokinetic and pharmacodynamic properties. Despite their significant potential, polyphenolic compounds are associated with limited bioavailability, primarily owing to low solubility, poor stability in the gastrointestinal tract, low intestinal permeability, and an extremely short plasma half-life [43].
Both DM and periodontal disease are associated with inflammatory processes and oxidative stress. The antioxidant defence system can be partially interrupted due to excessive production of free radicals, leading to altered inflammatory responses in individuals with underlying medical conditions, particularly those with diabetes. This suggests the potential benefits of additional anti-inflammatory treatment [20]. Various host immune system modulators could be used in addition to non-surgical periodontal treatment. A systematic review by Corbella et al. [45] discovered very low evidence regarding the adjunctive use of sub-antimicrobial doses of doxycycline, melatonin, and the combination of omega-3 and low-dose aspirin (in T2DM patients) to non-surgical periodontal treatment in modulating host response and improving PD and/or CAL. However, the evidence remains limited, and official recommendations for using host modulators in addition to periodontal treatment are lacking.
In our systematic review, three [27, 28, 30] of four human studies demonstrated a significant positive effect on periodontal status in patients with DM who consumed polyphenol supplements, although only one study [30] was evaluated as of high quality. In comparison to the control group, Gholinezhad et al. [30] observed a significant reduction in CAL and PD in 4 and 2.7 times, as well as Javid et al. [27] noticed an improvement in PD in 1.8 times. It is interesting that Javid et al. [28] found that omega-3 fatty acid, which acts as a host modulator exhibited a higher reduction in PD compared to cranberry juice. However, Javid et al. [29] reported no statistically significant reduction in CAL between the two groups post-intervention, even though CAL decreased significantly in both the intervention and control groups.
In spite of the fact that inflammation status in diabetic patients needs further investigations, the researchers observed positive effect while consuming polyphenol supplements. Ginger has been studied for its potential anti-inflammatory properties, and some authors have suggested that ginger extracts may inhibit the formation of inflammatory compounds, including prostaglandins and leukotrienes [46]. Gholinezhad et al. [30] highlighted significantly decreased levels of malondialdehyde and improved TAC in the intervention group, although these changes in inflammation markers did not reach statistical significance between the two groups post-intervention. Indeed, the findings suggest that resveratrol could have a beneficial impact on inflammatory processes. Its ability to activate antioxidant enzymes and suppress the release of proinflammatory cytokines such as TNF-α, IL-1β, IL-6, IL-10 and interferon-beta (IFN-β) in a wide range of tissues is of particular interest [47]. The findings from Javid et al. [29] suggest that resveratrol supplementation, when combined with non-surgical periodontal treatment, led to a significant decrease in IL-6 levels. However, when comparing the intervention group to the control group, no significant differences were observed in main inflammation markers such as IL-6, TNF-α, and TAC. The researchers highlighted an important consideration – while inflammatory markers reduced in response to common treatment, factors such as genetics, epigenetics, susceptibility, response variations, and other environmental circumstances could potentially interfere with the results. Consequently, they emphasised that the impact of polyphenols on inflammation degree cannot be conclusively determined.
The authors also reported improved DM parameters: Gholinezhad et al. [30] showed significantly decreased HbA1c and FBG levels in the intervention group; however, intergroup comparison revealed statistically significant improvement only in HbA1c values. Javid et al. [28] demonstrated significantly decreased HbA1c while consuming omega-3 fatty acid and cranberry juice, but overall changes in FBG and HbA1c levels were not significantly different between groups at baseline and post-intervention. Javid et al. [27] reported significantly improved insulin resistance, suggesting that polyphenols may act on common inflammatory processes in organisms. It has been established that dietary polyphenols play a significant role in treating type T2DM through insulin-dependent mechanisms. Curcumin has been shown to lower blood sugar and HbA1c. In addition, this polyphenol could enhance insulin sensitivity [48]. Likewise, resveratrol has been demonstrated to enhance glucose uptake and metabolism, promote pancreatic beta-cell protection, and improve insulin resistance [49].
Given the limited evidence from human studies, animal studies were also included in the review, revealing consistent positive outcomes. Across all investigations, the consumption of polyphenol substitutes resulted in a significant reduction in bone loss compared to control groups. Cirano et al. [33] demonstrated that resveratrol, either alone or combined with insulin, markedly decreased alveolar bone loss in diabetic animals compared to those receiving a placebo solution. Zhen et al. [36] reported a similar trend, showing that resveratrol treatment reduced alveolar bone loss in db/db mice with experimental periodontitis. Gennaro et al. [34] observed significantly diminished bone loss in diabetic rats ingesting green tea compared to those consuming water. Additionally, Catanzaro et al. [32] corroborated this observation, reporting that diabetic mice consuming green tea experienced less bone loss compared to those consuming water. Noteworthy findings emerged from the investigations by Alpan et al. [31] and Toker et al. [35], where different concentrations of taxifolin and grape seed proanthocyanidin were employed. Polyphenol administration significantly decreased alveolar bone loss, with no significant differences observed at higher concentrations. Nevertheless, Toker et al. [25] highlighted that polyphenol supplementation increased osteoblast activity. In the context of diabetes, which exacerbates pathological processes, including increased bone resorption and inhibited coupled bone formation, leading to accelerated bone loss, polyphenolic compounds exhibited favourable effects [50]. These compounds stimulated osteoblast proliferation, enhanced the OPG/RANKL ratio, and upregulated the expression of osteoblast differentiation markers. This heightened osteoblastic activity plays a crucial role in preventing alveolar bone loss and expediting mineralisation [51].
In all preclinical studies, a notable improvement in inflammation status was observed, characterised by significant reductions in ILs (IL-1β, IL-6 [33, 36], IL-8 [36], IL-10 [34]), TNF-α [34, 36], RANKL [31, 34], and nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [33]. In addition, Gennaro et al. [34] noticed that green tea intake increased the expression of the osteogenesis-related factor RUNX-2 and the anti-osteoclastogenic factor OPG. Toker et al. [35] highlighted the significant decrease in matrix metalloproteinase-8 (MMP-8) and hypoxia-inducible factor-1 alpha (HIF-1α) levels with grape seed proanthocyanidin extract. Finally, Zhen et al. [36] reported that resveratrol administration significantly suppressed elevated toll-like receptor 4 (TLR4) levels in gingival tissue of mice. Targeting these inflammatory mediators and reducing their activity holds potential benefits for patients with chronic periodontitis. The decrease in the production of ILs and TNF-α contributes to the regression of bone resorption and soft tissue injury [52]. NADPH oxidase, responsible for generating ROS, which can cause oxidative stress in periodontal tissues, saw lowered activity. This reduction in NADPH oxidase activity could lead to decreased ROS levels, thereby mitigating oxidative stress and its detrimental effects on periodontal tissues [53].
The DM condition in animals also garnered attention. Zhen et al. [36] discovered that resveratrol significantly lowered blood glucose levels compared to untreated mice with experimental periodontitis. Similarly, insulin and resveratrol therapy [33], green tea intake [32, 34] reduced hyperglycaemia in diabetic mice. In contrast, Toker et al. [35] did not observe any significant difference in blood glucose levels among the diabetic groups during the study. Also, Alpan et al. [31] confirmed that taxifolin did not affect blood glucose levels in diabetic mice. Exploring diabetes monitoring through polyphenol supplementation should be expanded, particularly given the promising results observed in other preclinical studies regarding the insulin-sensitising properties of polyphenols [54, 55].
After carefully examining the included studies, it is apparent that the current evidence regarding the positive effects of polyphenols on periodontal and DM status, as well as their anti-inflammatory properties, remains insufficient. While some studies have shown promising results in improving periodontal health and DM parameters, it is essential to acknowledge the limitations of the current literature, such as the high risk of bias in some clinical trials and the limited evidence regarding diabetes condition after polyphenol supplementation in human studies. The experimental conditions and findings from animal studies cannot be directly applied to clinical practice, as the biological processes studied in animal models may not precisely replicate those occurring in the human body. For these reasons, experimental animal studies are typically situated at the base of the evidence hierarchy and are considered to have the lowest level of evidence when evaluating the applicability of findings to human health and clinical practice. Also, one of the drawbacks of this systematic review is the restricted quantity of clinical trials, compounded by the fact that all investigations were carried out by a single research group. The authors of the included clinical studies assessed periodontal status using parameters such as PD and CAL. The clear impact of polyphenol supplementation in humans cannot be fully evaluated due to the lack of comprehensive information regarding alveolar bone loss, bleeding on probing, the number of missing teeth, etc. To establish the true potential of polyphenols as an adjunctive treatment for periodontal diseases, it is crucial to conduct long-term, well-designed observational studies and clinical trials. These studies should employ rigorous methodologies and include larger sample sizes to ensure robust and reliable outcomes.
Conclusion
The findings from this review preclude a definitive conclusion regarding the specific impact of polyphenols on periodontitis. Notably, the included preclinical studies provide substantial evidence to enhance our understanding of polyphenols’ effects, particularly in terms of reducing bone loss and improving glycaemic control. Further research and additional clinical studies may offer more comprehensive insights into the potential benefits of polyphenol supplementation in the context of periodontal health, especially in the presence of DM.
Data availability statement
Data related to the study are available upon request from via email to the corresponding author.
Geolocation information
Kaunas, Lithuania.
References
[1] Trindade D, Carvalho R, Machado V, et al. Prevalence of periodontitis in dentate people between 2011 and 2020: a systematic review and meta-analysis of epidemiological studies. J Clin Periodontol. 2023 May;50(5):604–26. https://doi.org/10.1111/jcpe.13769
[2] Kamer AR, Craig RG, Niederman R, et al. Periodontal disease as a possible cause for Alzheimer’s disease. Periodontol 2000. 2020 Jun;83(1):242–71. https://doi.org/10.1111/prd.12327
[3] Sanz M, Marco Del Castillo A, Jepsen S, et al. Periodontitis and cardiovascular diseases: consensus report. J Clin Periodontol. 2020 Mar;47(3):268–88. https://doi.org/10.1111/jcpe.13189
[4] Idrissi Janati A, Karp I, Latulippe JF, et al. Periodontal disease as a risk factor for sporadic colorectal cancer: results from COLDENT study. Cancer Causes Control. 2022 Mar;33(3):463–72. https://doi.org/10.1007/s10552-021-01541-y
[5] Gugnani S, Gugnani N. Is there any link between periodontitis and inflammatory bowel diseases? Evid Based Dent. 2023 Sep;24(3):127–9. https://doi.org/10.1038/s41432-023-00917-0
[6] de Molon RS, Rossa C, Jr, Thurlings RM, et al. Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions. Int J Mol Sci. 2019 Sep 13;20(18):4541. https://doi.org/10.3390/ijms20184541
[7] Aguiar ILS, Santos-Lins LS, Brasil-Oliveira R, et al. Non-alcoholic fatty liver disease and periodontal disease: a systematic review and meta-analysis of cross-sectional studies. Arab J Gastroenterol. 2023 Nov 21;24(4):198–203. https://doi.org/10.1016/j.ajg.2023.09.005
[8] Kim CM, Lee S, Hwang W, et al. Obesity and periodontitis: a systematic review and updated meta-analysis. Front Endocrinol (Lausanne). 2022 Oct 24;13:999455. https://doi.org/10.3389/fendo.2022.999455
[9] Păunică I, Giurgiu M, Dumitriu AS, et al. The bidirectional relationship between periodontal disease and diabetes mellitus – a review. Diagnostics (Basel). 2023 Feb 11;13(4):681. https://doi.org/10.3390/diagnostics13040681
[10] Baker JL, Mark Welch JL, Kauffman KM, et al. The oral microbiome: diversity, biogeography and human health. Nat Rev Microbiol. 2023 Sep 12;22:89–104. https://doi.org/10.1038/s41579-023-00963-6
[11] Bhuyan R, Bhuyan SK, Mohanty JN, et al. Periodontitis and its inflammatory changes linked to various systemic diseases: a review of its underlying mechanisms. Biomedicines. 2022 Oct 21;10(10):2659. https://doi.org/10.3390/biomedicines10102659
[12] Slots J. Periodontitis: facts, fallacies and the future. Periodontol 2000. 2017 Oct;75(1):7–23. https://doi.org/10.1111/prd.12221
[13] Xin X, Xiang X, Xin Y, et al. Global trends in research on oxidative stress associated with periodontitis from 1987 to 2022: a bibliometric analysis. Front Immunol. 2022 Sep 8;13:979675. https://doi.org/10.3389/fimmu.2022.979675
[14] Carneiro Sczepanik FS, Grossi ML, Casati M, et al. Periodontitis is an inflammatory disease of oxidative stress: we should treat it that way. Periodontology 2000. 2020;84(1):45–68. doi: 10.1111/prd.12342
[15] Vincent RR, Appukuttan D, Victor DJ, et al. Oxidative stress in chronic periodontitis patients with type II diabetes mellitus. Eur J Dent. 2018 Apr–Jun;12(2):225–31. https://doi.org/10.4103/ejd.ejd_244_17
[16] Toy VE, Ataoglu T, Eltas A, et al. Obesity as a modifying factor of periodontal therapy outcomes: local and systemic adipocytokines and oxidative stress markers. Clin Oral Investig. 2023 Jun;27(6):2763–73. https://doi.org/10.1007/s00784-022-04854-7
[17] Rana A, Samtiya M, Dhewa T, et al. Health benefits of polyphenols: a concise review. J Food Biochem. 2022 Oct;46(10):e14264. https://doi.org/10.1111/jfbc.14264
[18] Delpino FM, Figueiredo LM. Resveratrol supplementation and type 2 diabetes: a systematic review and meta-analysis. Crit Rev Food Sci Nutr. 2022;62(16):4465–80. https://doi.org/10.1080/10408398.2021.1875980
[19] Buglio DS, Marton LT, Laurindo LF, et al. The role of resveratrol in mild cognitive impairment and Alzheimer’s disease: a systematic review. J Med Food. 2022 Aug;25(8):797–806. https://doi.org/10.1089/jmf.2021.0084
[20] Stöhr J, Barbaresko J, Neuenschwander M, et al. Bidirectional association between periodontal disease and diabetes mellitus: a systematic review and meta-analysis of cohort studies. Sci Rep. 2021 Jul 1;11(1):13686. https://doi.org/10.1038/s41598-021-93062-6
[21] Mehriz BM, Atteya MA, Skipina TM, et al. Association between periodontitis and diabetes mellitus in the general population. J Diabetes Metab Disord. 2022 Sep 30;21(2):1249–54. https://doi.org/10.1007/s40200-022-01010-6
[22] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009 Jul 21;6(7):e1000097. https://doi.org/10.1371/journal.pmed.1000097
[23] Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011 Oct 18;343:d5928. https://doi.org/10.1136/bmj.d5928
[24] Hooijmans CR, Rovers MM, de Vries RB, et al. SYRCLE’s risk of bias tool for animal studies. BMC Med Res Methodol. 2014 Mar 26;14:43. https://doi.org/10.1186/1471-2288-14-43
[25] Giménez-Siurana A, Gómez García F, Pagan Bernabeu A, et al. Chemoprevention of experimental periodontitis in diabetic rats with silk fibroin nanoparticles loaded with resveratrol. Antioxidants (Basel). 2020 Jan 19;9(1):85. https://doi.org/10.3390/antiox9010085
[26] Effect of resveratrol usage as an adjunct to scaling and root planning in Type II Diabetic patients [Internet]. [cited 04-04-2023]. Available from: https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2022/05/042806
[27] Zare Javid A, Hormoznejad R, Yousefimanesh HA, et al. The impact of resveratrol supplementation on blood glucose, insulin, insulin resistance, triglyceride, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Phytother Res. 2017 Jan;31(1):108–14. https://doi.org/10.1002/ptr.5737
[28] Zare Javid A, Maghsoumi-Norouzabad L, Ashrafzadeh E, et al. Impact of cranberry juice enriched with omega-3 fatty acids adjunct with nonsurgical periodontal treatment on metabolic control and periodontal status in type 2 patients with diabetes with periodontal disease. J Am Coll Nutr. 2017 Dec;37(1):71–9. https://doi.org/10.1080/07315724.2017.1357509
[29] Javid AZ, Hormoznejad R, Yousefimanesh HA, et al. Impact of resveratrol supplementation on inflammatory, antioxidant, and periodontal markers in type 2 diabetic patients with chronic periodontitis. Diabetes Metab Syndr. 2019 Jul–Aug;13(4):2769–74. https://doi.org/10.1016/j.dsx.2019.07.042
[30] Gholinezhad H, Bazyar H, Rashidi H, et al. Using ginger supplement in adjunct with non-surgical periodontal therapy improves metabolic and periodontal parameters in patients with type 2 diabetes mellitus and chronic periodontitis: a double-blind, placebo-controlled trial. J Herb Med. 2020;20:100315. https://doi.org/10.1016/j.hermed.2019.100315
[31] Lektemur Alpan A, Bakar O, Kızıldağ A, et al. Effects of taxifolin on bone formation and apoptosis in experimental periodontitis in diabetic rats. Biotech Histochem. 2022 May;97(4):306–14. https://doi.org/10.1080/10520295.2021.1977997
[32] Catanzaro DP, Mena Laura EE, Cestari TM, et al. Green tea prevents vascular disturbs and attenuates periodontal breakdown in long-term hyperglycaemia in T1D rats. J Clin Periodontol. 2018 May;45(5):557–69. https://doi.org/10.1111/jcpe.12883
[33] Cirano FR, Molez AM, Ribeiro FV, et al. Resveratrol and insulin association reduced alveolar bone loss and produced an antioxidant effect in diabetic rats. J Periodontol. 2021 May;92(5):748–59. https://doi.org/10.1002/JPER.19-0718
[34] Gennaro G, Claudino M, Cestari TM, et al. Green tea modulates cytokine expression in the periodontium and attenuates alveolar bone resorption in type 1 diabetic rats. PLoS One. 2015 Aug 13;10(8):e0134784. https://doi.org/10.1371/journal.pone.0134784
[35] Toker H, Balci Yuce H, Lektemur Alpan A, et al. Morphometric and histopathological evaluation of the effect of grape seed proanthocyanidin on alveolar bone loss in experimental diabetes and periodontitis. J Periodontal Res. 2018 Jun;53(3):478–86. https://doi.org/10.1111/jre.12536
[36] Zhen L, Fan DS, Zhang Y, et al. Resveratrol ameliorates experimental periodontitis in diabetic mice through negative regulation of TLR4 signaling. Acta Pharmacol Sin. 2015 Feb;36(2):221–8. https://doi.org/10.1038/aps.2014.131
[37] Thouvenot K, Turpin T, Taïlé J, et al. Links between insulin resistance and periodontal bacteria: insights on molecular players and therapeutic potential of polyphenols. Biomolecules. 2022 Feb 28;12(3):378. https://doi.org/10.3390/biom12030378
[38] Nawrot-Hadzik I, Matkowski A, Hadzik J, et al. Proanthocyanidins and Flavan-3-Ols in the prevention and treatment of periodontitis-antibacterial effects. Nutrients. 2021 Jan 7;13(1):165. https://doi.org/10.3390/nu13010165
[39] Wang Y, Zeng J, Yuan Q, et al. Efficacy of (-)-epigallocatechin gallate delivered by a new-type scaler tip during scaling and root planing on chronic periodontitis: a split-mouth, randomized clinical trial. BMC Oral Health. 2021 Feb 18;21(1):79. https://doi.org/10.1186/s12903-021-01418-1
[40] Das M, Das AC, Panda S, et al. Clinical efficacy of grape seed extract as an adjuvant to scaling and root planing in treatment of periodontal pockets. J Biol Regul Homeost Agents. 2021 Mar–Apr;35(2 Suppl. 1):89–96. https://doi.org/10.23812/21-2supp1-8
[41] Chava VK, Vedula BD. Thermo-reversible green tea catechin gel for local application in chronic periodontitis: a 4-week clinical trial. J Periodontol. 2013 Sep;84(9):1290–6. https://doi.org/10.1902/jop.2012.120425
[42] Elavarasu S, Suthanthiran T, Thangavelu A, et al. Evaluation of superoxide dismutase levels in local drug delivery system containing 0.2% curcumin strip as an adjunct to scaling and root planing in chronic periodontitis: a clinical and biochemical study. J Pharm Bioallied Sci. 2016 Oct;8(Suppl. 1):S48–52. https://doi.org/10.4103/0975-7406.191967
[43] Jayusman PA, Nasruddin NS, Mahamad Apandi NI, et al. Therapeutic potential of polyphenol and nanoparticles mediated delivery in periodontal inflammation: a review of current trends and future perspectives. Front Pharmacol. 2022 Jul 12;13:847702. https://doi.org/10.3389/fphar.2022.847702
[44] Chedea VS, Macovei ȘO, Bocșan IC, et al. Grape pomace polyphenols as a source of compounds for management of oxidative stress and inflammation – a possible alternative for non-steroidal anti-inflammatory drugs? Molecules. 2022 Oct 12;27(20):6826. https://doi.org/10.3390/molecules27206826
[45] Corbella S, Calciolari E, Alberti A, et al. Systematic review and meta-analysis on the adjunctive use of host immune modulators in non-surgical periodontal treatment in healthy and systemically compromised patients. Sci Rep. 2021 Jun 9;11(1):12125. https://doi.org/10.1038/s41598-021-91506-7
[46] Al-Shibani N, Al-Kattan R, Alssum L, et al. Effects of ginger (Zingiber officinale) on gingival fibroblasts: an in vitro study. Clin Exp Dent Res. 2022 Aug;8(4):906–11. https://doi.org/10.1002/cre2.575
[47] Chin YT, Cheng GY, Shih YJ, et al. Therapeutic applications of resveratrol and its derivatives on periodontitis. Ann N Y Acad Sci. 2017 Sep;1403(1):101–8. https://doi.org/10.1111/nyas.13433
[48] Naz R, Saqib F, Awadallah S, et al. Food polyphenols and type II diabetes mellitus: pharmacology and mechanisms. Molecules. 2023 May 10;28(10):3996. https://doi.org/10.3390/molecules28103996
[49] Su M, Zhao W, Xu S, et al. Resveratrol in treating diabetes and its cardiovascular complications: a review of its mechanisms of action. Antioxidants (Basel). 2022 May 30;11(6):1085. https://doi.org/10.3390/antiox11061085
[50] Zhou M, Graves DT. Impact of the host response and osteoblast lineage cells on periodontal disease. Front Immunol. 2022 Oct 11;13:998244. https://doi.org/10.3389/fimmu.2022.998244
[51] Torre E. Molecular signaling mechanisms behind polyphenol-induced bone anabolism. Phytochem Rev. 2017;16(6):1183–226. https://doi.org/10.1007/s11101-017-9529-x
[52] Jiang Q, Zhao Y, Shui Y, et al. Interactions between neutrophils and periodontal pathogens in late-onset periodontitis. Front Cell Infect Microbiol. 2021 Mar 12;11:627328. https://doi.org/10.3389/fcimb.2021.627328
[53] Zhang YL, An Y, Sun LJ, et al. NADPH-dependent ROS accumulation contributes to the impaired osteogenic differentiation of periodontal ligament stem cells under high glucose conditions. Front Endocrinol (Lausanne). 2023 Jun 7;14:1152845. https://doi.org/10.3389/fendo.2023.1152845
[54] Na LX, Zhang YL, Li Y, et al. Curcumin improves insulin resistance in skeletal muscle of rats. Nutr Metab Cardiovasc Dis. 2011 Jul;21(7):526–33. https://doi.org/10.1016/j.numecd.2009.11.009
[55] Lee YE, Kim JW, Lee EM, et al. Chronic resveratrol treatment protects pancreatic islets against oxidative stress in db/db mice. PLoS One. 2012;7(11):e50412. https://doi.org/10.1371/journal.pone.0050412